Antitumoral effects of lipids a, clinical studies

Advances in Experimental Medicine and Biology

Volumn 667, Issue , 2009, Pages 125-131

  Reisser, Danièle ^a   Bardou, Marc ^b  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 DEOXY 3 O (9 PHENYLNONANOYL) 2 [3 (9 PHENYLNONANOYLOXY)TETRADECANOYLAMINO]GLUCOPYRANOSE 4 SULFATE; CANCER GROWTH FACTOR; INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPID A; LIPID A DERIVATIVE; OM 174; PHOSPHORYL LIPID A; SDZ MRL 953; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL INFECTION; CANCER IMMUNOLOGY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; CYANOSIS; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPOTENSION; HYPOTHERMIA; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; INNATE IMMUNITY; LIVER TOXICITY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RIGOR; SEPSIS;

ANIMALS; HUMANS; LIPID A; NEOPLASMS;

ANIMALIA;

EID: 77952481712     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-1603-7_11     Document Type: Article

References (43)

1. Cress RD, Morris C, Ellison GL et al. Secular changes in colorectal cancer incidence by subsite, stage at diagnosis and racc/ethniciry, 1992-2001. Cancer 2006; 107(5 Suppl):1142-1152. (Pubitemid 44384820)
2. Becker N, Altenburg HP, Stegmaier C et al. Report on trends of incidence (1970-2002 ) of and mortalit y (1952-2002) from cancer in Germany. J Cancer Res Clin Oncol 2006.
3. Levi F, Lucchini F, La Vecchia C. Trends in cancer mortality in Switzerland, 1980-2001. Eur J Cancer Prev 2006; 15(1):1-9. (Pubitemid 43048737)
4. West J, Wood H. Logan RF et al. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer 2006; 94(11 ):1751-1758. (Pubitemid 43924943)
5. Hoyerr DL, Heron MP, Murph y SL et al. Deaths: final data for 2003. Natl Vital Stat Rep 2006; 54(13):1-120.
6. Evans C, Dalgleish AG, Kumar D. Review article: immune suppression and colorectal cancer. Aliment Pharmacol Ther 2006; 24(8):1163-1177. (Pubitemid 44427504)
7. Carpenti er AF, Meng Y. Recent advances in immunotherapy for human glioma. Curt Opin Oncol 2006; 18(6):631-636. (Pubitemid 44427639)
8. van de Wiel PA, van der Pijl A. Bloksma N. Role of tumour necrosis factor in the tum our-necrotizing activity of agents with diverging toxicity. Cancer Immunol Irnrnunorher 1991; 33(2):115-120.
9. Blondiau C, Lagadec P, Lejeune P et al. Correlation between the capacity to activate macrophages in vitro and the antitumor activity in vivo of lipopolysaccharides from different bacterial species. Immunobiology 1994; 190(3):243-254. (Pubitemid 24145642)
10. Inagawa H. Nishizawa T. Takagi K et al. Antitumor mechanism of intradermal administration of lipopolysaccharide. Anticancer Res 1997; 17(3C):1961-1964. (Pubitemid 27320934)
11. Shimizu T, !ida K, Iwamoto Y et al. Biologicalactivities and antitumor effects of synthetic lipid A analog linked N-acylated serine. Int J Immunopharmacol1995; 17(5):425-431.
12. Onier N, Lejeune P, Martin M et al. Involvement of T-Iymphocytes in curative effect of a new imrnunornodulator OM 163 on rat colon cancer metastases. Eur J Cancer 1993; 29A(14) :2003-2009. (Pubitemid 23324362)
13. On ier N, Hilpert S, Arnould L et al. Cure of colon cancer metastasis in rats with the new lipid A OM 174. Apoptosis of tumor cells and immunization of rats. Clin Exp Metastasis 1999; 17(4):299-306. (Pubitemid 29477575)
14. Lagadec P, Raynal S. Lieubeau B et al. Evidence for control of nitric oxide synthesis by intracellular transforming growth factor-beta1 in tumor cells. Implications for tumor development. Am J Pathol 1999; 154(6):1867-1876. (Pubitemid 29262870)
15. Coley WB. The treatment of inoperable sarcoma with the mixed toxins of Erysipelas and bacillus prodigiosus. j Am Med Assoc 1898; 31:589-595.
16. Shear MJ, Turner Fe. Chemical treatment of tumors. V. Isolation of the hemorrhage-producing fraction from Serratia rnarcescens (Bacillus prodigiosus) culture filtrate. J Natl Cancer Inst 1943; 4(81-97).
17. Parr I, Wheeler E, Alexander P. Similarities of the anti-tumour actions of endotoxin, lipid A and double -stranded RNA. Br J Cancer 1973; 27(5) :370-389.
18. Reisser D, Pance A, Jeannin JF. Mechanisms of the antitumoral effect of lipid A. Bioessays 2002; 24:284-289. (Pubitemid 34248695)
19. Matzinger P. Tolerance, danger and the extended family. Annu Rev Immunol1994; 12:991-1045.
20. Verhasselc V. Buelens C, Willems F et al. Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CDI4-dependent pathway. J Immuno11997; 158(6):2919-2925. (Pubitemid 127470554)
21. Ismaili J, Rennesson J, Aksoy E et al. Monophosphoryllipid A activates both human dendritic cells and T-cells. J Immunol 2002; 168(2):926-932. (Pubitemid 34049597)
22. Vosika GJ, Barr C, Gilbertson D. Phase-I study of intravenous modified lipid A. Cancer Immuno l Imrnunother 1984; 18(2):107-112. (Pubitemid 15213363)
23. Rcisser D, Arnould L, Maynadie M et al. Lipid A OM-174 increases the natural killer activity of peripheral blood cells from breast cancer patients. J Endotoxin Res 1999; 5(4) :189-195. (Pubitemid 30011964)
24. Engelhardt R. Mackensen A, Galanos C. Phase 1 trial of intravenously administered endotox in (Salmonella abortus equi) in cancer patients. Cancer Res 1991; 51(10) :2524-2530.
25. Mackensen A, Galanos C, Wehr U et al. Endotoxin tolerance : regulation of cytokine production and cellular changes in response to endotoxin application in cancer patients. Eur Cytokine Netw 1992; 3(6) :571-579.
26. Mackensen A, Galanos C, Engelhardt R. Modulating activity of interferon-gamma on endotoxin-induced cytokine production in cancer patients. Blood 1991; 78(12):3254-3258.
27. de Bono JS, Dalgleish AG, Carmichael Jet al. Phase I study of ON0-4007. a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin Cancer Res 2000; 6(2) :397-405. (Pubitemid 30111456)
28. Otto F, Schmid P, Mackensen A et al. Phase II trial of intravenous endotoxin in patients with colorectal and nonsmall cell lung cancer. Eur J Cancer 1996; 32A(1O):1712-1718. (Pubitemid 26306882)
29. Kiani A, Tschiersch A, Gaboriau E et al. Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients. Blood 1997; 90(4) :1673-1683. (Pubitemid 27355442)
30. van Devenrer SJ, Buller HR, ten Care JW et al. Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 1990; 76(12) :2520-2526.
31. Goto S, Sakai S, Kera J et al. Intradermal administration of lipopolysaccharide in treatment of human cancer. Cancer Immunol Immunother 1996; 42(4) :255-261. (Pubitemid 26183208)
32. Engelhardt R, Otto F, Mackensen A et al. Endotoxin (Salmonella abortus equi) in cancer patients. Clinical and immunological findings. Prog Clin Biol Res 1995; 392:253-261.
33. Matsuura M, Kiso M, HasegawaA. Activity of monosaccharide lipid A analoguesin human monocytic cells as agonises or antagonists of bacterial lipopolysaccharide. Infect Immun 1999; 67(12 ):6286-6292.
34. Tarnai R, Asai Y, Hashimoto M et al. Cell activation by monosaccharide lipid A analogues utilizing Toll-like receptor 4. Immunology 2003; 110(1):66-72. (Pubitemid 37059673)
35. Martin M. Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryllipid A. Infect Immun 2003; 71(5) :2498-2507. (Pubitemid 36519862)
36. Saha DC, Barna RS. Astiz ME et al. Monophosphoryllipid A stimulated up-regulation of reactiveoxygen intermediates in human monocytes in vitro. J Leukoc Biol 2001; 70(3):381-385. (Pubitemid 32826125)
37. Matsumoto N, Aze Y,Akimoto A et al. ON0-4007. an antitumor lipid A analog, induces tumor necrosis factor-alpha production by human monocyres only under primed state : different effects of ON0-4007 and lipopolysaccharide on cytokine production. J Pharmacol Exp Ther 1998; 284(1) :189-195. (Pubitemid 28109545)
38. Walzer T. Dalod M. Robbins SH et al. Natural-killer cells and dendritic cells: "l'union fait la force" Blood 2005 ; 106(7) :2252-2258. (Pubitemid 41510793)
39. Magder S. Neculcea J. Neculcea V et aL Lipopolysaccharide and TNF-alpha produce very similar changes in gene expression in human endothelial cells. J Vase Res 2006; 43(5):447-461. (Pubitemid 44402083)
40. Christophi C. Winkworth A. Muralihdaran V et al. The treatment of malignancy by hyperthermia. Surg Onco11998; 7(1-2):83-90. (Pubitemid 29273924)
41. Dinarello CA. Infection. fever and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res 2004; 10(4):201-222. (Pubitemid 39481010)
42. Engelhardt R. Mackensen A, Galanos C et al. Biological response to intravenously administered endotoxin in patients with advanced cancer. J Biol Response Mod 1990; 9(5) :480-491. (Pubitemid 20366161)
43. Hoption Cann SA, van Nerren JP, van Nerren C. Dr Will iam Coley and tumour regression: A place in history or in the future. Postgrad Med J 2003; 79(938) :672-680. (Pubitemid 38134682)